TabsDetailsBasic DetailsDate Posted: Wednesday, May 10, 2017Status: CompleteMedical Product: BCR-ABL, BRAF, BRCA, KRAS, afatinib dimaleate, bosutinib, cetuximab, cobimetinib fumarate, dabrafenib mesylate, dasatinib, erlotinib HCL, estimated glomerular filtration rate (eGFR), gefitinib, imatinib mesylate, nilotinib HCL, olaparib, osimertinib mesylate, panitumumab, ponatinib HCL, trametinib dimethyl sulfoxide, vemurafenibHealth Outcome(s): cancerDescription: This project contains three reports. Report 1 contains estimates of drug use among patients with a prior genetic test and/or relevant cancer diagnosis. Report 2 contains estimated distribution of baseline covariates among members receiving various genetic tests: KRAS, BRAF, EGFR, BCR-ABL, and BRCA. Report 3 contains estimates of drug initiation following genetic testing among patients with relevant cancers.The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2013 to December 31, 2015. The request was distributed to 14 Data Partners on June 17, 2016. Read More Deliverables (3)Sentinel Modular Program Report: Drug Use Following Genetic Testing Among Patients with Cancer, Report 1Sentinel Modular Program Report: Drug Use Following Genetic Testing Among Patients with Cancer, Report 2Sentinel Modular Program Report: Drug Use Following Genetic Testing Among Patients with Cancer, Report 3Additional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2013 - December 31, 2015Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Sentinel Distributed Database (SDD)
